Filtered By:
Drug: Activase

This page shows you your search results in order of date. This is page number 17.

Order by Relevance | Date

Total 1186 results found since Jan 2013.

Intravenous Thrombolytics in the Treatment of Acute Ischemic Stroke
AbstractPurpose of ReviewTo review the current evidence and ongoing clinical trials evaluating the efficacy and safety of tenecteplase (TNK), an alternative tissue plasminogen activator (tPA), in the acute management of arterial ischemic stroke (AIS). To date, alteplase is the only tPA approved by the United States FDA for use in AIS.Recent FindingsThere have been multiple phase two and three trials investigating the safety and efficacy of TNK in AIS. In patients with AIS due to large vessel occlusion, one randomized controlled trial demonstrated superiority of TNK for vessel recanalization rates and long-term functional o...
Source: Current Treatment Options in Cardiovascular Medicine - January 2, 2023 Category: Cardiology Source Type: research

Tenecteplase Versus Alteplase in Routine Clinical Practice Tenecteplase Versus Alteplase in Routine Clinical Practice
This paper details the results of a hospital network ' s transition from alteplase to tenecteplase as the standard of care for stroke thrombolysis. How did costs and clinical outcomes compare?Stroke
Source: Medscape Today Headlines - December 29, 2022 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news

Comparative efficacy and safety of tenecteplase and alteplase in acute ischemic stroke: A pairwise and network meta-analysis of randomized controlled trials
Studies on tenecteplase have been yielding mixed results on several important variables at different doses, thus hampering objective guideline recommendations in acute ischemic stroke management. This meta-analysis stratifies doses in order to refine our interpretation of outcomes and quantify the benefits and harms of tenecteplase at different doses.
Source: Journal of the Neurological Sciences - December 28, 2022 Category: Neurology Authors: Aqeeb Ur Rehman, Aleenah Mohsin, Huzaifa Ahmad Cheema, Afra Zahid, Muhammad Ebaad Ur Rehman, Muhammad Zain Ameer, Muhammad Ayyan, Muhammad Ehsan, Abia Shahid, Muhammad Aemaz Ur Rehman, Jaffer Shah, Ayaz Khawaja Tags: Review Article Source Type: research

Factors associated with functional disability in patients with acute stroke excluded from alteplase administration due to minor non-disabling neurological deficits
ConclusionModerate motor weakness presentation and LAD may be important factors associated with poor functional outcomes in patients with acute stroke excluded from alteplase administration due to mild symptoms.
Source: Frontiers in Neurology - December 22, 2022 Category: Neurology Source Type: research

Predictors of malignant middle cerebral artery infarction after endovascular thrombectomy: results of DIRECT-MT trial
ConclusionsReperfusion, serum glucose, ASPECTS, CBS, collateral, and pass number of thrombectomy device were associated with the occurrence of mMCAi in stroke patients after EVT, while alteplase treatment was not. Our findings might facilitate the early identification and management of stroke patients at a high risk of mMCAi.Key Points• A total of 13.2% of stroke patients with large vessel occlusion of anterior circulation developed mMCAi after EVT.• The occurrence of mMCAi had a definite negative impact on the outcome for stroke patients.• Reperfusion, serum glucose, ASPECTS, CBS, collateral score, and the pass numb...
Source: European Radiology - December 15, 2022 Category: Radiology Source Type: research

Benefit and risk of intravenous alteplase in patients with acute large vessel occlusion stroke and low ASPECTS
Conclusions Bridging IVT in patients with low ASPECTS was associated with very poor functional outcome and an increased risk of sICH. The benefit of this treatment should therefore be carefully weighed in such scenarios. Further randomized controlled trials are required to validate our findings.
Source: Journal of NeuroInterventional Surgery - December 14, 2022 Category: Neurosurgery Authors: Broocks, G., McDonough, R., Bechstein, M., Hanning, U., Brekenfeld, C., Flottmann, F., Kniep, H., Nawka, M. T., Deb-Chatterji, M., Thomalla, G., Sporns, P., Yeo, L. L., Tan, B. Y., Gopinathan, A., Kastrup, A., Politi, M., Papanagiotou, P., Kemmling, A., F Tags: Open access, Editor''s choice, Ischemic stroke Source Type: research

Economic evaluation of intravenous alteplase for stroke with the time of onset between 4.5 and 9 hours
Conclusion For patients with AIS with a time of onset between 4.5 and 9 hours, perfusion imaging-guided intravenous alteplase was likely to be cost-effective in China and was cost-effective in the US when compared with placebo.
Source: Journal of NeuroInterventional Surgery - December 14, 2022 Category: Neurosurgery Authors: Chen, J., Liang, X., Tong, X., Han, M., Ji, L., Zhao, S., Hu, Z., Liu, A. Tags: Open access, Socioeconomics Source Type: research

Outcomes with IV tenecteplase and IV alteplase for acute ischemic stroke with or without thrombectomy in real-world settings in the United States
J Stroke Cerebrovasc Dis. 2022 Dec 6;32(2):106898. doi: 10.1016/j.jstrokecerebrovasdis.2022.106898. Online ahead of print.NO ABSTRACTPMID:36493706 | DOI:10.1016/j.jstrokecerebrovasdis.2022.106898
Source: Atherosclerosis - December 9, 2022 Category: Cardiology Authors: Adnan I Qureshi William I Baskett Navpreet K Bains Brandi R French Farhan Siddiq Camilo R Gomez Chi-Ren Shyu Source Type: research

EE568 Tenecteplase or Alteplase for Acute Ischemic Stroke? A Cost-Effectiveness Analysis
Alteplase is widely used as intravenous thrombolytic medication in acute ischemic stroke (AIS). However, tenecteplase, a genetically modified form of alteplase, has recently been shown to result in higher recanalization rates, improved functional outcome and a similar safety profile in AIS patients with large vessel occlusion (LVO) compared to alteplase. Accordingly, this study aims to evaluate the cost-effectiveness of 0.25mg/kg tenecteplase versus 0.9mg/kg alteplase for thrombolysis in AIS patients due to LVO from the Dutch healthcare payer perspective.
Source: Value in Health - December 1, 2022 Category: International Medicine & Public Health Authors: C Nguyen, MMH Lahr, DJ Van der Zee, H Van Voorst, YBWEM Roos, M Uyttenboogaart, E Buskens Source Type: research

The efficacy and safety of tenecteplase versus alteplase for acute ischemic stroke: an updated systematic review, pairwise, and network meta-analysis of randomized controlled trials
AbstractTenecteplase (TNK) is a promising candidate to replace alteplase as the standard of care for acute ischemic stroke (AIS); however, the optimal dosage is still to be investigated. Therefore, we aim to evaluate the safety and efficacy of TNK versus alteplase and to investigate the optimal TNK dosage. A systematic review, pairwise, and network meta-analysis synthesizing randomized controlled trials (RCTs) from WOS, SCOPUS, EMBASE, and PubMed until July 26th, 2022. We used the risk ratio (RR) for dichotomous outcomes presented with the corresponding 95% confidence interval (CI). We registered our protocol in PROSPERO w...
Source: Journal of Thrombosis and Thrombolysis - November 30, 2022 Category: Hematology Source Type: research

Tenecteplase in managing acute ischemic stroke: a long-term cost-utility analysis in Iran
CONCLUSIONS: Base-case and sensitivity analysis showed that TNK is the dominant strategy compared to ALT for the management of AIS patients.PMID:36420792 | DOI:10.1080/14737167.2023.2152008
Source: Expert Review of Pharmacoeconomics and Outcomes Research - November 24, 2022 Category: Health Management Authors: Kosar Hajian Ramin Abdi Dezfouli Ali Darvishi Ramin Radmanesh Ramin Heshmat Source Type: research